Our Company

Transforming Scientific Advancements into better Life Science solutions for tomorrow.

As your trusted strategic partner, it is our mission to positively impact a sustainable life science ecosystem connecting deep knowledge, cutting-edge technologies, and highly skilled personnel. We are dedicated to delivering on the drug discovery, early drug development and manufacturing goals of the biotech and pharma industry with high quality, speed and flexibility.

Bioneer is a strategic partner to a broad range of biotech and pharmaceutical companies globally. We have a 40-year proven track record of delivering impact to the life science ecosystem in the Nordics as well as internationally as a Danish government-approved Research and Technology Organization (RTO).

We are an R&D-driven CRO and CDMO dedicated to continuing to develop and expand our customized, innovative, and high-quality research and manufacturing service solutions to help companies:

  • discover, develop and produce promising early drug candidates and recombinant proteins; and
  • deliver key pre-clinical insights into the mechanisms, efficacy, safety, and formulation of early drug candidates.

As your trusted strategic partner, it is our mission to positively impact a sustainable life science ecosystem connecting deep knowledge, cutting-edge technologies, and highly skilled personnel. We are dedicated to delivering on the drug discovery, early drug development and manufacturing goals of the biotech and pharma industry with high quality, speed and flexibility.

Bioneer is a strategic partner to a broad range of biotech and pharmaceutical companies globally. We have a 40-year proven track record of delivering impact to the life science ecosystem in the Nordics as well as internationally as a Danish government-approved Research and Technology Organization (RTO).

We are an R&D-driven CRO and CDMO dedicated to continuing to develop and expand our customized, innovative, and high-quality research and manufacturing service solutions to help companies:

  • discover, develop and produce promising early drug candidates and recombinant proteins; and
  • deliver key pre-clinical insights into the mechanisms, efficacy, safety, and formulation of early drug candidates.

Locations

Bioneer is located in the heart of Medicon Valley.
We have two sites in Denmark serving our partners globally.

Hørsholm – Denmark

Our main site and headquarters is located in Hørsholm, 20 minutes north of Copenhagen, in the heart of the Scion-DTU Science Park.
This 3350m2 site is equipped with both offices and state-of-the-art lab facilities. Overall the site has 1400m2 office space, 450m2 of warehouse and 1500m2 of laboratory space.

Copenhagen – Denmark

We have a site located at the Department of Pharmacy at the University of Copenhagen, Bioneer:FARMA.
This 180m2 site has offices and laboratories, It was established in 2007 in collaboration with the University of Copenhagen.

Hørsholm – Denmark

Our main site and headquarters is located in Hørsholm, 20 minutes north of Copenhagen, in the heart of the Scion-DTU Science Park.
This 3350m2 site is equipped with both offices and state-of-the-art lab facilities. Overall the site has 1400m2 office space, 450m2 of warehouse and 1500m2 of laboratory space.

Copenhagen – Denmark

We have a site located at the Department of Pharmacy at the University of Copenhagen: Bioneer:FARMA.
This 180m2 site has offices and laboratories. It was established in 2007 in collaboration with the University of Copenhagen.

Leadership

Our dedicated team is looking forward to adding value to your programs.

Lars Hagsholm Pedersen
Lars Hagsholm PedersenCEO, Ph.D.

Lars H. Pedersen has an M.Sc. in Biology from the University of Copenhagen, a Ph.D. in plant membrane proteins from the Technical University of Denmark, and a business education from the Engineering College of Copenhagen. He has hands-on experience with molecular diagnostics, cell technology, protein production and medico technology. He was CSO at Bioneer for twelve years where his research focused on a combination of life and physical science. Before being appointed CEO of Bioneer in April 2018, he was heading Sales and Business Development for four years, where the main task was to tailor Bioneer’s activities to meet the demands of clients.
Christian Clausen
Christian ClausenCSO, M.Sc.

Christian Clausen was educated in biochemistry and medical science at the University of Southern Denmark and Odense University Hospital, with research visits at Aarhus University Hospital. He has also completed R&D management programs at Harvard Business School, Boston. His research experience is primarily in the human cell biology field, especially in developing in vitro model systems and recombinant protein production. He was previously R&D Manager at Interface Biotech, leading several pipeline programs from preclinical to clinical phase. He has extensive experience in executive management of large national and international public-private partnerships. As CSO he is responsible for the overall R&D strategy and for external strategic collaborations across the Bioneer organization.
Jette Asboe Lassen
Jette Asboe LassenCBO, M.Sc.

Jette Asboe Lassen brings more than 20 years of business experience from her leadership roles in therapeutic and diagnostic life science companies in both the US and Europe. Prior to joining Bioneer, she served as Vice President and Head of Business Development and Alliance Management at Symphogen, a clinical stage oncology company developing antibody therapeutics. A commercial mindset combined with a robust understanding of science has enabled her to successfully guide product pipeline prioritization, transition ideas/programs into strong selling propositions, and execute and manage significant strategic alliances with pharmaceutical and diagnostic companies globally. She did her commercial training in the US and has since been the commercial lead during all stages of development from discovery through to product launch. As Chief Business Officer, she has the overall responsibility for Business Development and Marketing at Bioneer.
Kia Norsker
Kia NorskerCFO, Cand.merc.aud

Kia Norsker has a M.Sc. (Business Economics & Auditing) from the Copenhagen Business School and nine years of experience as an external auditor at Deloitte and EY Denmark.
During those years she worked with both listed and medium sized private companies within different industries including life science and manufacturing.
Kia has an in-depth understanding of Bioneer and Bioneer’s business from her six years serving as external auditor for the company prior to her taking on the role as Bioneer’s CFO in 2021.
As CFO Kia has the overall responsibility for Finance and Accounting at Bioneer.
Jens Chr. Norrild
Jens Chr. NorrildCCO, Ph.D.

Jens Chr. Norrild has a M.Sc. in organic chemistry from University of Copenhagen, a Ph.D. in carbohydrate chemistry from The Technical University of Denmark, and an Executive Certificate in ”Managing Medical Product Innovation” from Copenhagen Business School. Jens has more than 25 years of experience form Danish biotech and pharma and among others held the position as CMC Project Director at Novo Nordisk bringing numerous medical products from research into the clinic. Later, as VP of CMC and Quality in Cytoki Pharma, Jens contributed to building a new clinical stage biotech company by securing cGMP production of a novel biologics and building a Quality Management System. Jens has during his pharma career spearheaded collaboration with many CMO’s and CDMO’s and knows how to create a mutual fruitful and flexible collaboration environment that fosters high quality results and provide impact for both parties. As Chief CDMO Officer Jens has the overall responsibility for Bioneer’s, CDMO organization.
Søren Madsen
Søren MadsenProtein Expression, Dept. Head, Ph.D.

Heads the Protein Manufacturing Group in Hørsholm, managing R&D and customer relations, and handling projects from small-scale protein production to downstream processing.
Anette Müllertz
Anette MüllertzBioneer:FARMA, Dept. Head, Professor

Anette Müllertz heads the site of Copenhagen: Bioneer:FARMA, located at the Department of Pharmacy at the University of Copenhagen. She is also a professor in Pharmaceutical Design and Drug Delivery.
Pernille Skouboe
Pernille SkouboeRA/QA Manager, Adm. Dept. Head, M.Sc.

Responsible for quality assurance and regulatory compliance objectives within R&D services and GMP production.
Bjørn Holst
Bjørn HolstCellular Engineering & Disease Modelling, Dept. Head, Ph.D.

Heads the Biomedical Technology department in Hørsholm and is responsible for the advanced Disease Model group.
Charlotte Kvist LorentzenContract Manufacturing, Dept. Head, M.Sc.

Heads the Contract Manufacturing department at Bioneer, over 20 years of experience.

Board of Directors

Our Board has a profound insight into the pharmaceutical, biotech and medtech industries as well as in research and contributes to Bioneer’s position as a strong research-based development partner

Karin GarreChairman

Karin brings extensive leadership, change management, and drug development experience from over 30 years in the life science industry, encompassing roles in pharmaceutical and biotech companies such as Astra A/S, Novo Nordisk A/S, Genmab and most recently Symphogen A/S. In addition to various leading positions in line and project functions in pharmaceutical R&D she has held executive positions as c-suite member or CEO in industry and in the Danish health care sector. Karin came to Symphogen in 2018 and was appointed General Manager in 2020 when the company was acquired by Servier Pharmaceutical. In this role, she lead the change management process and integration of Symphogen into Servier’s global R&D function as the Center of Excellence for Antibodies. Upon completion, Karin decided to enter a new career path as of 2024. Karin is very much engaged in strategic and organizational performance aiming to combine science, technologies, and know-how, transforming opportunities into value for patients. She is focused on maintaining an inspiring and motivating working culture. Karin holds an MD from Copenhagen University. During her career she has held various board positions – currently she is on the board at Expres2ion Biotechnology and Cervello A/S. Further Karin runs her own advisory business, Garre Transformation.
Marianne ThellersenDep. Chairman

Marianne comes to the board with many years of biotech industry experience prior to her present position at DTU where she heads all activities concerning the creation of commercial value from scientific results. Marianne has an M.Sc. in Biotechnology from DTU and an e-MBA from CBS-SIMI. She first joined Novo Nordisk and later Novozymes where she held a range of positions related to research and innovation. Marianne was Program Director at CBS-Simi for two years before becoming SVP at DTU in 2012. Marianne is deeply engaged in how innovative research can be converted into viable societal and commercial value and is instrumental in creating a vibrant entrepreneuria environment at DTU campuses. Marianne represents DTU (the owner) and contributes to Bioneers societal and business activities with her many years of insight into technology transformation processes.
Bjarke Bak ChristensenBoard member

Bjarke Bak Christensen has a Ph.D. in Microbiology from the Technical University of Denmark (DTU) and worked as a research scientist at Danish Food and Veterinary Research Institute, where he became Head of Section in 2004. In 2007 he became Head of Research Division Microbiology and Risk Assessment at DTU Food. From 2010 to 2016 Bjarke headed Department of Food Science at University of Copenhagen (FOOD), which he left in order to become Head of Department of Biotechnology and Biomedicine at DTU, which is offering research and education within biotechnology, microbiology, biochemistry and pharma technology. Bioneer is benefitting from Bjarke’s profound knowledge and knowhow concerning novel trends and scientific developments in the food science, biotechnology and pharma areas.
Trine WinterøBoard member

Trine is a well known authority in the management of innovation processes and in the operationalization of novel business ideas at the interface of business, science and technology. Trine has a Ph.D in Molecular Genetics from The Royal Veterinary and Agricultural University where she later became Associate Professor. Her business career started in 2001 in her role as Innovation Manager of Symbion Science Park, and she later became the CEO of Symbion Management and Symbion Capital, an early stage venture fund. In 2008 she founded Medtech Innovation Consortium (MTIC) as CEO. At MTIC she was the main driver in building an entrepreneurial and creative product and service development environment between medtech companies, start-ups in the field, and health institutions. In 2016 she joined the University of Copenhagen in the role of Vice Dean for innovation at the Faculty of Health and Medical Sciences. Here, her task is to support the creation of a productive innovation system. Trine contributes to the Board with her many years of experience with public- private partnerships and in the management of innovation.
Mads LaustsenBoard member

Mads Laustsen is a well-known and highly respected Danish biotech CEO and entrepreneur with over 35 years of experience within large and medium sized biopharma companies as well as small life science start-ups. After 15 years combined at Novo Nordisk, Zymogenetics and Novozymes Mads co-founded CMC-Biologics where he was CEO for more than 10 years. Following the acquisition of CMC-Biologics by AGC, Mads became CMO of Symphogen and later co-founded Bactolife where he was CEO for 6 years before becoming an independent Strategic Advisor. Mads brings with him many years of valuable technical experience within Biologics development and manufacturing from the biotech and pharmaceutical industry and has extensive experience in managing both small and large companies. Furthermore, Mads possesses in-depth knowledge of initiating and operating biotech companies and currently serves on the Board of three other companies.
Lone VengBoard member

Lone Veng is an experienced, entrepreneurial and strategically minded C-Suite executive with a proven track record of building companies both as CEO and non-executive Director. Lone has 13 years of ‘Big Pharma’ experience from Lundbeck, Merck Research Laboratories and Leo Pharma where she has worked primarily with small molecule drug development. She was appointed CEO of Clinical Microbiomics in 2015 and was CEO of Resother Pharma from 2017 to 2023. From her time at these companies, Lone brings comprehensive experience within project leadership including setting business and therapeutic area strategies. Her leadership approach focuses on formulating and clearly communicating strategy, optimizing the business to deliver quality, and on building competence and enthusiasm in organizations. Currently, Lone sits on the Board of two other companies.
Lasse SaabyBoard member

Pharmaceutical Development, Head of Operations, Ph.D., Bioneer
Monika GadBoard member

Cellular Engineering and Disease Modelling, Team Manager, Ph.D., Bioneer.
Marianne Imer BønnelyckeBoard member

Laboratory Technician, Bioneer.

GTS

From science to societal value

Bioneer A/S is a not-for-profit organization and a subsidiary of the Technical University of Denmark (DTU). It is approved by the Danish Ministry of Science and Technology as an authorized provider of technological services – a GTS entity.

Our public mission is two-fold. First, to provide tools and technologies that facilitate early implementation of new therapeutic strategies in the Danish health sector. Second, to contribute to making Denmark a front-runner in very early commercialization of biomedical research as a means to grow the Danish biotech industry.

GTS is the Danish Association of Research and Technology Organizations that connects technology and businesses.

The seven Danish government-approved Research and Technology Organization (GTS institutes) play a key role in the Danish innovation system as the link between technology and business. They seek to make new technological methods applicable to businesses and promote businesses uptake of new technology.

Read more about the GTS entities here.

Latest news

Discover and read our latest news.